The heterogeneity of the endogenous and polyI:C-induced levels of TLR3 protein in the lung cancer cell lines provide us with good models to investigate the differential impact of polyI:C on survival and metastatic potential as a means to understand why Hiltonol (a drug analogue of polyI:C) elicited differential therapeutic efficacy in cancer patients. This evidence concerns the gene TLR3 and lung cancer.